Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Asthma treating pharmaceutical composition

A composition and drug technology, applied in the field of medicine, can solve the problems of poor patient effect

Inactive Publication Date: 2018-09-25
郭秋玲
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still a small number of patients who respond poorly to this treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Asthma treating pharmaceutical composition
  • Asthma treating pharmaceutical composition
  • Asthma treating pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0021] The characterization of experimental example 1 medicine of the present invention

[0022]

[0023] 1 H NMR (400MHz, CDCl 3 ):δ10.85(s,1H),9.86(s,1H),8.02(d,J=13.1Hz,1H),6.65(dd,J=8.7,7.7Hz,2H),4.53(d,J= 3.9Hz, 2H), 4.40(t, J=5.1Hz, 1H), 4.18(s, 2H), 3.42(s, 6H), 3.39(m, 2H), 3.37(s, 3H).

[0024] 13 C NMR (100MHz, CDCl 3 ): δ193.30, 169.15, 162.10 (ddd, J = 248.9, 15.5, 15.5Hz), 161.7 (ddd, J = 250.0, 14.9, 11.1Hz), 161.66, 111.08 (ddd, J = 19.9, 19.9, 4.7Hz) 103.12 ,100.29(ddd,J=28.1,17.7,2.3Hz),76.30,58.83,54.98,53.53,51.57,29.89(t,J=3.3Hz).

experiment example 2

[0025] Experimental example 2 The therapeutic effect of medicine of the present invention for asthma

[0026] Sixty healthy female Kunming mice were randomly divided into a normal group of 10 and a model group of 30 after weighing.

[0027] Preparation of Mouse Allergic Asthma Model

[0028] Mice in the model group were induced by mites (HDM) as a mouse allergic asthma model: after mixing 25 μg of crude HDM extract with 10 μL of 0.9% NaCl, each mouse was intranasally instilled with 10 μL each time, 5 times a week, for 7 consecutive days. week. The mice in the normal group were intranasally instilled with 10 μL of normal saline, and the procedure was the same as above.

[0029] Animal grouping and dosing

[0030] The model mice were divided into a model group, a positive control group and a drug group of the present invention, with 10 mice in each group.

[0031] After 5 weeks of sensitization, the mice of the drug group of the present invention were administered with 10 mg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an asthma treating pharmaceutical composition, which comprises a compound and any one or a variety of pharmaceutically acceptable carriers. The invention further discloses uses of the compound in preparation of asthma treating drugs, wherein the compound can be prepared in any one pharmaceutically acceptable preparation. According to the present invention, the asthma treating pharmaceutical composition can reduce the high-level expression of IL-17, IL-6, TNF-alpha and TGF-beta in pulmonary alveoli due to allergic asthma, can improve the pathological changes oflung tissue to a certain extent, and has a certain anti-inflammatory and anti-pulmonary fibrosis effect so as to achieve the purpose of asthma treating drugs.

Description

technical field [0001] The invention relates to the field of medicine, in particular, the invention relates to a pharmaceutical composition for treating asthma. Background technique [0002] Allergic asthma is the release of mediators mediated by IgE after exposure to allergens in atopic individuals. It is a chronic airway inflammatory response disease involving a variety of immune active cells and cytokines. Most patients respond well to treatment with inhaled corticosteroids and β-adrenoceptor agonists. However, there are still a small number of patients who respond poorly to this treatment. Contents of the invention [0003] The object of the present invention is to provide a pharmaceutical composition for treating asthma. [0004] In order to realize the purpose of the present invention, the present invention provides a kind of pharmaceutical composition for treating asthma, and described pharmaceutical composition comprises the component with following formula struc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/165A61P11/06
CPCA61K31/165
Inventor 郭秋玲
Owner 郭秋玲
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com